Atyr PHARMA (NASDAQ:ATYR) Upgraded by Leerink Partnrs to "Strong-Buy" Rating

Leerink Partnrs upgraded shares of Atyr PHARMA (NASDAQ:ATYR - Free Report) to a strong-buy rating in a research note issued to investors on Tuesday,Zacks.com reports. Leerink Partnrs also issued estimates for Atyr PHARMA's Q4 2024 earnings at ($0.21) EPS, FY2024 earnings at ($0.89) EPS, Q1 2025 earnings at ($0.21) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.71) EPS, FY2026 earnings at ($0.56) EPS, FY2027 earnings at $0.16 EPS, FY2028 earnings at $1.29 EPS and FY2029 earnings at $1.82 EPS.

A number of other brokerages have also weighed in on ATYR. HC Wainwright restated a "buy" rating and set a $35.00 price objective on shares of Atyr PHARMA in a research note on Tuesday, December 10th. Cantor Fitzgerald started coverage on Atyr PHARMA in a research report on Monday, January 6th. They set an "overweight" rating for the company. Finally, Leerink Partners started coverage on Atyr PHARMA in a research report on Tuesday. They set an "outperform" rating and a $16.00 price objective for the company. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Atyr PHARMA presently has a consensus rating of "Buy" and an average target price of $18.60.

Atyr PHARMA Trading Down 2.5 %

Shares of Atyr PHARMA stock traded down $0.11 during trading hours on Tuesday, reaching $4.32. The stock had a trading volume of 1,767,908 shares, compared to its average volume of 987,059. The firm has a market capitalization of $362.62 million, a price-to-earnings ratio of -4.60 and a beta of 1.10. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. Atyr PHARMA has a 1 year low of $1.42 and a 1 year high of $4.66. The firm has a 50 day simple moving average of $3.61 and a two-hundred day simple moving average of $2.87.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ATYR. Federated Hermes Inc. acquired a new position in shares of Atyr PHARMA in the 4th quarter valued at $53,093,000. Point72 Asset Management L.P. acquired a new position in shares of Atyr PHARMA in the 4th quarter valued at $17,677,000. Tikvah Management LLC acquired a new position in shares of Atyr PHARMA in the 4th quarter valued at $8,908,000. Woodline Partners LP acquired a new position in shares of Atyr PHARMA in the 4th quarter valued at $6,092,000. Finally, Alyeska Investment Group L.P. acquired a new position in shares of Atyr PHARMA in the 4th quarter valued at $4,628,000. Institutional investors and hedge funds own 61.72% of the company's stock.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.